Sunday, 23 August 2026European Markets
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Work with this data → vianewsagency.com

ADOCIA Stock Went Up By Over 20% In The Last 10 Sessions

Loading stream...

(vianews) - shares of adocia (cac 40: adoc.pa) rose by a staggering 20.92% in 10 sessions from €3.27 to €3.96 at 17:37 est on thursday, after five sequential sessions in a row of losses. cac 40 is jumping 0.16% to €7,214.16, following the last session's downward trend.

adocia's last close was €3.96, 38.7% below its 52-week high of €6.46.

about adocia

adocia sa, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. its proprietary biochaperone technological platform provides molecular delivery of therapeutic proteins. the company's clinical product pipeline includes insulin formulations, such as biochaperone lispro u100 and u200, which are ultra-rapid formulations based on rapid insulin lispro; biochaperone combo, a combination of acting insulin glargine and rapid-acting insulin lispro; biochaperone lispram, a combination of prandial insulin with pramlintide; and biochaperone glucagon, an aqueous formulation of human glucagon for the treatment of hypoglycemia, as well as m1pram, a metabolite of insulin glargine and pramlintide. its preclinical pipeline includes products for the treatment of diabetes and obesity comprising adoshell islets, an implant containing islets of langerhans; adoral sema, an oral delivery of semaglutide; and biochaperone gluexe, a combination of glucagon and exenatide. the company has a strategic alliance with tonghua dongbao pharmaceutical co., ltd. to develop and commercialize biochaperone lispro and biochaperone combo in china and other asian and middle eastern territories. adocia sa was incorporated in 2005 and is headquartered in lyon, france.

earnings per share

as for profitability, adocia has a trailing twelve months eps of €-0.99.

revenue growth

year-on-year quarterly revenue growth grew by 312.1%, now sitting on 13.95m for the twelve trailing months.

yearly top and bottom value

adocia's stock is valued at €3.96 at 17:37 est, way under its 52-week high of €6.46 and way higher than its 52-week low of €2.80.

volume

today's last reported volume for adocia is 61713 which is 19.2% above its average volume of 51391.

moving average

adocia's value is way higher than its 50-day moving average of €3.58 and higher than its 200-day moving average of €3.96.

more news about adocia (adoc.pa).